Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00073580
Status:
COMPLETED
Last Update Posted:
2018-11-30
First Post:
2003-11-26
Brief Title:
Angiomax in Patients With HITHITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting CABG CHOOSE
Sponsor:
The Medicines Company
Organization:
The Medicines Company
Study Overview
Official Title:
Angiomax in Patients With HITHITTS Type II Undergoing Off-PUMP CABG
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia HITheparin-induced thrombocytopenia with thrombosis syndrome HITTS undergoing off-pump coronary artery bypass OPCAB surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CHOOSE | None | None | None |